K
Kamada
Pharmaceutical Development by Using a Unique Protein Purification Technology
About Kamada
Kamada Ltd. is a biopharmaceutical company specializing in the development, production, and commercialization of plasma-derived protein therapeutics. Founded in 1990 and headquartered in Rehovot, Israel, Kamada operates in the global healthcare market, primarily serving patients with rare and serious conditions such as pulmonary emphysema, liver disease, and cytomegalovirus (CMV) infections. The company is publicly traded on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol KMDA.
Kamada's core business revolves around its proprietary technology for the extraction and purification of proteins from human plasma. This technology enables the company to produce a range of therapeutic products, including its flagship product, Glassia, an intravenous treatment for Alpha-1 Antitrypsin (AAT) deficiency. AAT deficiency is a genetic disorder that can lead to severe lung and liver diseases. Kamada also offers KamRAB, a rabies immunoglobulin, and is developing additional products targeting unmet medical needs.
The company's business model is built on a combination of direct sales and strategic partnerships. Kamada generates revenue through the sale of its products to hospitals, clinics, and healthcare providers, as well as through licensing agreements and collaborations with other pharmaceutical companies. For instance, Kamada has a long-standing partnership with Takeda Pharmaceuticals for the distribution of Glassia in the United States.
Kamada's growth strategy focuses on expanding its product portfolio, enhancing its manufacturing capabilities, and entering new markets. The company is also investing in research and development to advance its pipeline of innovative therapies, which includes treatments for graft-versus-host disease (GVHD) and COVID-19.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1990
- Headquarters
- Ness Ziyyona, Israel
- Listing
- IPO 2013
- Employees
- 359
- Open positions
- 28
- Dealroom signal
- 48.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Testing, Social, Health, Developer Tools, Biotechnology, Therapeutics, Injections
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VC✓Other financing | May 2023 | $60M | — | FIMI | ↗ |
| POST IPO EQUITYOther financing | Jan 2020 | $25M | — | FIMI | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Kamada is 10K monthly website visits, up 63.9% over the last three months. Kamada's team grew 55.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Hercules Capital
FIMI
Other known investors1 additional known investor
- SBSivan Baram
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kamada on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kamada’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.